Background Myocardial injury after non-cardiac surgery (MINS) increases the risk of
cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran …

Background—The perioperative management of dabigatran in clinical practice is
heterogeneous. We performed this study to evaluate the safety of perioperative …

Background—Dabigatran reduces ischemic stroke in comparison with warfarin; however,
given the lack of antidote, there is concern that it might increase bleeding when surgery or …

Acutely Injured Patients on Dabigatran | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Background The original RE-LY (Randomized Evaluation of Long-term Anticoagulant
Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of …

Abstract▲ Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a
potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced …

Background—The aim of this study was to compare the management and prognosis of
major bleeding in patients treated with dabigatran or warfarin. Methods and Results—Two …

Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following
oral administration, dabigatran etexilate is rapidly converted to its active form, dabigatran …

Background Signals of an increased risk of myocardial infarction (MI) have been identified
with dabigatran etexilate in randomized controlled trials (RCTs). Methods and Resules We …

Background—Left ventricular assist device–supported patients are usually anticoagulated
with a combination of aspirin and vitamin K antagonists. Long-term vitamin K antagonist …